Eli Lilly develops and sells pharmaceutical treatments across multiple therapeutic areas globally, including the United States, Europe, Asia, and other international markets. The company's portfolio spans cardiometabolic conditions such as diabetes and obesity, oncology treatments for various cancers, immunology medications, and therapies for migraine, cluster headache, and Alzheimer's disease. The firm also maintains partnerships and licensing agreements with other pharmaceutical companies to expand its research and development capabilities in areas including diabetes care, oncology, genetic medicines, and neurological treatments.

entry readiness 42 · WEAK SETUP · exit proximity 0

Value area 981.28–1,283.75 · 43% of 120d volume overhead · moderate overhead